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Inhibition of neointimal hyperplasia in vascular grafts by sus-
tained perivascular delivery of paclitaxel.
Background. Neointimal hyperplasia occurs commonly at the
anastomoses of arteriovenous grafts for chronic hemodialysis,
causing stenosis and occlusion. Antiproliferative drugs may be
effective in inhibiting hyperplasia, but local drug delivery would
be required to minimize systemic side effects. We examined the
feasibility of local drug delivery to inhibit neointimal hyperpla-
sia at dialysis grafts in a canine model.
Methods. Bilateral polytetrafluoroethylene loop grafts (10-
cm length and 6-mm internal diameter) were placed between
the femoral artery and ipsilateral femoral vein of five mongrel
dogs. At the time of surgery or 1 to 5 weeks later, 2 mL of
a thermosensitive biodegradable copolymer (ReGel) mixed
with 0.26 mg or 0.65 mg paclitaxel were applied to the external
surface of one graft around the anastomoses to provide a depot
for sustained release of the drug. ReGel alone without paclitaxel
was applied to the contralateral graft as a control. The grafts and
the connecting vessels were explanted at eight or nine weeks,
and the cross-sections were examined histologically. The degree
of hyperplasia at the anastomoses was graded by five blinded
independent reviewers, with scores ranging from 0 to 5.
Results. The median (25th–75th percentile) hyperplasia score
of both arterial and venous anastomoses was 1.80 (0.90–3.05)
in the grafts treated with ReGel alone, and 0.95 (0.70–1.50) in
the grafts treated with ReGel/paclitaxel (N = 8; P < 0.05 by
Wilcoxon signed rank test). There were no noticeable localized
or systemic complications attributed to the treatments in these
animals. Paclitaxel levels in the plasma obtained from forelimb
veins were undetectable (<10 ng/mL).
Conclusion. These results suggest that the local delivery
of antiproliferative agents using a thermosensitive, injectable
biodegradable copolymer (ReGel) for sustained delivery is a
promising strategy to inhibit neointimal hyperplasia of arteri-
ovenous hemodialysis grafts.
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Stenosis followed by thrombosis is the major cause of
failure of hemodialysis vascular grafts. Stenosis occurs
most commonly at the venous anastomosis, but it also oc-
curs not infrequently at the arterial anastomosis [1]. In
recent years, extensive efforts have been devoted to the
monitoring of graft patency [2–5] and mechanical treat-
ment of the stenotic lesions [6]. Stenosis that has been
subjected to balloon angioplasty, however, is prone to
recurrence, because of the injury that angioplasty can
produce in the vessel wall. In fact, balloon angioplasty
is a classic method of inducing neointimal hyperplasia in
animal carotid artery models [7]. Therefore, prevention
of stenosis, rather than mechanical revascularization, is
a more sound approach to maintain the functioning of
dialysis grafts.
The stenotic lesions associated with polytetrafluo-
roethylene (PTFE) grafts are mostly myointimal hyper-
plasia upon histologic examination, which is composed of
proliferating vascular smooth muscle cells, extracellular
matrix, and neo-microvasculature that feeds the growing
and migrating cells [8, 9]. Therefore, the focal inhibition of
smooth muscle cell proliferation and migration would ap-
pear to be a reasonable approach to prevent graft stenosis.
Systemic treatment with antiproliferative agents is pos-
sible and has been attempted with limited success, but
local treatment appears to be a more reasonable strat-
egy, since the hyperplastic lesions are often localized and
would be less likely to produce systemic side effects [1].
Further, unlike neoplastic cells, the proliferating cells in
these lesions do not metastasize. Since the stenosis occurs
most commonly at venous and arterial anastomoses, the
administration of antiproliferative drugs to the anasto-
moses would likely prevent the proliferation of cells at
those sites.
The pathogenesis of neointimal hyperplasia has not
been fully elucidated. While the initial tissue injury as-
sociated with the graft placement may promote neointi-
mal hyperplasia, some of the processes that predispose to
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the development of hyperplasia are not transient. These
may include the mismatch of vessel sizes and compliance,
localized flow disturbances, and the release of growth fac-
tors from the vascular wall and adhering platelets in re-
sponse to dialysis needle puncture. Therefore, sustained
rather than a single delivery of antiproliferative agents
may be necessary to prevent stenosis chronically.
Various techniques have been developed for sus-
tained local drug delivery. The specific method em-
ployed in the present study is unique in that the delivery
platform, ReGel (MacroMed, Inc., Sandy, UT, USA)
is injectable [10]. Therefore, the depot can be re-
plenished periodically as needed to maintain sus-
tained release over extended time. ReGel is a triblock
polymer of polylactide-co-glycolide-polyethyleneglycol-
polylactide-co-glycolide with a molar ratio of lac-
tide:glycolide of 3:1. The property of ReGel that allows it
to be injectable is the temperature-dependent reversible
transition between liquid and gel phase. The copolymer
dissolves in water to form a free-flowing liquid at 2 to 8◦C
and turns into a water-insoluble gel immediately upon ex-
posure to body temperature. Thus, ReGel can be mixed
with drugs in the aqueous phase and injected using a 22- to
25-gauge hypodermic needle into the body, where it will
form a gel depot for sustained-release of the drugs over
several weeks. The drugs are released from ReGel ini-
tially by diffusion, and later by a combination of diffusion
and degradation of the matrix. Additional advantages
of this co-polymer are as follows: (1) organic solvents
are not used for its formulation; (2) it is non-pyrogenic,
non-cytotoxic, non-mutagenic, and does not elicit any sig-
nificant inflammatory response; (3) it will dissolve both
hydrophilic and hydrophobic drugs; (4) it has a long
shelf life (more than two years at −10◦C even in liquid
form); (5) it is totally biodegradable; therefore, there is no
need for surgical removal. The degradation products are
polyethylene glycol, lactic acid and glycolic acid in very
small quantities (1–2 mmol of each compound per mL
of gel). These products are on the G.R.A.S. (Generally
Recognized as Safe) list, and should be readily metab-
olized or removed by low-flux or high-flux hemodialysis
membranes.
The present study utilized the local and sustained deliv-
ery of paclitaxel by ReGel. Paclitaxel is an antiprolifera-
tive agent that is effective against normal vascular smooth
muscle cells [11, 12], in addition to various malignant cells
[13]. By virtue of its action to stabilize microtubules [14],
paclitaxel inhibits mitosis and the migration of vascular
smooth muscle cells. Paclitaxel delivered by drug-eluting
stents has been used clinically to prevent coronary artery
restenosis [15]. The in vivo kinetics of release of paclitaxel
from ReGel have also been defined using the radiola-
beled drug [10]. After injection of ReGel with paclitaxel
into a tumor in mice, the drug dissipated from the tumor
slowly over 6 to 8 weeks. Almost 70% of the drug was
excreted in the feces, with only 3% excreted in the urine,
and <0.1% distributed in the other organs combined.
METHODS
Canine model of arteriovenous PTFE grafts
All animal procedures and care were performed in
accordance with the “Principles of Laboratory Animal
Care” and the “Guidelines for the Care and Use of
Laboratory Animals” (NIH publication no. 80–23, re-
vised 1985), and approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of
Utah and the Veterans Affairs Salt Lake City Healthcare
System. Mongrel dogs of either gender weighing 16 to
20 kg, and expanded PTFE (ePTFE) grafts with internal
diameter of 6 mm (Gore-Tex vascular graft; W.L. Gore
& Associates, Inc., Flagstaff, AZ, USA) were used in all
experiments.
Anesthesia was induced using xylazine (1.1–2.2 mg/kg
intramuscularly). The animals were endotracheally intu-
bated, and general anesthesia was maintained using 1.5%
to 3.0% isoflurane. Under sterile conditions, a 10-cm long
ePTFE loop graft was implanted between the femoral
artery and the ipsilateral femoral vein on one side of
the animal, with the arterial-graft anastomosis (hereto-
fore known as arterial anastomosis) and the venous-graft
anastomosis (heretofore known as venous anastomosis)
adjacent to each other. Intramuscular buprenorphine was
given postoperatively for analgesia as needed. No antico-
agulants or antiplatelet agents were used before, during,
or after the graft implantation procedure. Graft patency
was monitored weekly by palpation, auscultation using a
stethoscope and a doppler.
In some pilot studies designed to explore the time
course of stenosis formation, the animals were euthanized
at 2, 4, or 8 weeks (N = 2–6 for each time point) by in-
travenous injection of pentobarbital (80–100 mg/kg). The
ePTFE graft was then excised along with approximately
2 cm of the proximal and distal artery and vein segments
adjacent to the anastomoses. The explant was immedi-
ately preserved in 10% buffered formalin for histologic
examination as described below.
Intervention and monitoring
Based on the results of the pilot studies, the follow-
ing series of experiments were performed. Five mongrel
dogs were subjected to graft placement using a proce-
dure identical to that described above for the pilot stud-
ies, with the exception that placement of bilateral instead
of unilateral grafts were performed between a femoral
artery and vein. Immediately after graft placement or af-
ter a variable interval of 1 to 5 weeks (see Table 1 for
details), paclitaxel (0.26–0.65 mg of Genexol, Samyang
Genex, Inc., Taejon, Korea) contained in 2 mL of ReGel
(MacroMed, Inc.) was applied to the external surface of
Masaki et al: Paclitaxel and vascular grafts 2063
Table 1. Time course and paclitaxel dosage for individual animals
Animal Time of drug Dose of paclitaxel Time of animal Graft patency Graft patency
number application in ReGel sacrifice ReGel alone ReGel/paclitaxel
1 At surgery 0.26 mg 8 weeks 8 weeks 8 weeks
2 1 week 0.65 mg 8 weeks 8 weeks 8 weeks
3 2 weeks 0.26 mg 8 weeks 8 weeks 8 weeks
4 4 weeks 0.26 mg 8 weeks 4 weeks 8 weeks
5 5 weeks 0.26 mg 9 weeks 9 weeks 9 weeks
The specified dosage of paclitaxel was mixed with 2 mL of ReGel and applied in gel form at the time of surgery (animal #1), or injected in liquid form at 1 to 5 weeks
(animals #2–5) to the graft on one side. The contralateral graft that received ReGel alone served as a control. The grafts were patent at the time of sacrifice (8 or 9
weeks) in all animals, except for the graft that received ReGel alone in animal #4, which was occluded after 4 weeks.
the graft and native vessels at the site of the anastomoses
on one side. The contralateral graft was treated in an iden-
tical manner with ReGel alone and served as a control.
The side of the animal that received the ReGel/paclitaxel
instead of ReGel alone was selected at random by person-
nel with no knowledge about the details of the surgery. In
one of these five animals, ReGel and ReGel/paclitaxel in
gel form were applied directly to the surface of the ves-
sels before wound closure. The administration of ReGel
and ReGel/paclitaxel was delayed for 1 to 5 weeks in
the other four animals. Those animals were sedated us-
ing intramuscular ketamine (5–7 mg/kg) and the 2 mL
of ReGel or ReGel/paclitaxel were injected in six small
boluses around the anastomoses using an 18-gauge hypo-
dermic needle and a 3-mL syringe.
The surgical wound and graft patency were monitored
up to eight or nine weeks postoperatively. Peripheral
blood was obtained weekly from a forelimb vein. Plasma
concentrations of paclitaxel in the blood samples were
measured by a commercial enzymatic immunoassay kit
(Hawaii Biotechnology Group, Inc., Aiea, HI, USA).
At eight or nine weeks after graft placement, the
dogs were euthanized using intravenous pentobarbital
(80–100 mg/kg). The bilateral ePTFE grafts were ex-
cised along with approximately 2 cm of the proximal
and distal arterial, and venous segments adjacent to the
anastomoses. The explants were immediately placed in
Karnovsky buffer. After one week, the samples were
fixed in 10% buffered formalin until they were subjected
to histologic analyses as described below.
The timing of drug administration, the dose of pacli-
taxel, and the time of sacrifice for each of the five animals
are presented in Table 1.
Histologic examination and scoring for neointimal
hyperplasia
Following fixation using 10% buffered formalin, the ex-
planted tissues were processed through graded alcohol,
xylene, and paraffin and embedded in paraffin blocks.
Multiple 8- to 10-lm cross sections were obtained at
2-mm intervals. The slides were stained with hematoxylin
and eosin (H&E). The sections of tissues from the pi-
lot studies were also stained with trichrome, van Gieson,
alcian blue, and an antihuman a-actin monoclonal anti-
body that was visualized using a second antibody and an
alkaline phosphatase chromagen developing kit (Dako,
Carpinteria, CA, USA).
The sections from the five animals with bilateral grafts
were used for semiquantitation of neointimal hyperpla-
sia. The arterial and venous anastomoses were graded
separately in slides with the best cross-sections, although
all the available slides were examined. The degree of hy-
perplasia in the H&E sections was scored by five inde-
pendent observers who were blinded to the treatment
that the particular graft received (ReGel/paclitaxel vs.
ReGel alone). The scores ranged from 0 to 5, with 0.5
unit increments allowed. Tissue ingrowth overlying the
luminal surface of the graft adjacent to the anastomosis
was considered to be neointimal hyperplastic tissue. It
was agreed upon among the observers before the scoring
that total occlusion of the lumen in either the graft or the
inflow/outflow tract by neointimal hyperplasia would be
arbitrarily scored as a “5.” The cross-sectional area oc-
cupied by a thrombus, either occlusive or nonocclusive,
would be disregarded. Minimal lining of the graft lumen
or the native vessel wall by hyperplastic tissues would be
considered as a “0.5.” An exemplary slide was used to
define the score of “0.5” before scoring started. It was
reckoned that minimal hyperplasia in the native vessel
wall was sometimes difficult to determine. All intermedi-
ate scores between 0.5 and 5.0 were decided exclusively
by individual observers with no preset standards.
Statistical analysis
The numerical scores for each anastomosis were aver-
aged based on the scores from the five observers to de-
termine a composite numerical score. Only the average
scores are presented in Figure 4 and used in the follow-
ing statistical analyses. The scores for the arterial anasto-
moses in the grafts treated with ReGel were compared
to those for the arterial anastomoses in the grafts treated
with ReGel/paclitaxel using the Wilcoxon signed-rank
test. Similarly, the differences between the scores for the
venous anastomoses on both sides were also examined.
Finally, the scores for both arterial and venous anasto-
moses on the sides treated with ReGel were compared
2064 Masaki et al: Paclitaxel and vascular grafts
A B
C D
E
Masaki et al: Paclitaxel and vascular grafts 2065
to the corresponding scores on the other sides treated
with ReGel/paclitaxel using the same statistical tech-
nique. A P value less than 0.05 was considered statistically
significant.
RESULTS
Surgery and postoperative conditions
After an initial learning period, the surgery of graft
placement was generally uneventful. Perioperative an-
ticoagulation was unnecessary to prevent immediate
thrombosis. Erythema in the skin overlying the graft was
a consistent feature, which was attributed to foreign-body
reactions to the ePTFE graft, and disappeared after ap-
proximately a week without antibiotic treatment. There
was no obvious wound infection or hemorrhage in these
animals. A commonly observed problem, however, re-
lates to animal hyperactivity and attempts to bite the sur-
gical wound; therefore, protective collars were required.
Histology in pilot studies
The pilot studies in which the animals were sacrificed at
various time points suggested that eight weeks were re-
quired for a reasonable degree of stenosis to manifest
at the venous anastomosis. The hyperplastic tissues at
eight weeks were comprised of nucleated cells in disarray
(Fig. 1A). These cells reacted strongly with anti-a actin
(Fig. 1B), suggesting that they were derived from vas-
cular smooth muscle cells. In addition, there were abun-
dant extracellular matrices that stained prominently with
trichrome (Fig. 1C), van Gieson (Fig. 1D), and alcian
blue (Fig. 1E), suggesting that they were rich in collagen,
elastin, and acid mucopolysaacharide, respectively. The
median hyperplasia score was 1.55 with an interquartile
range of 1.10 to 2.40 (25th–75th percentile) at the arterial
anastomoses, and 2.40 with an interquartile range of 1.10
to 3.50 at the venous anastomoses. The median score of
both arterial and venous anastomoses combined was 1.70
with an interquartile range of 1.10 to 3.30.
Graft patency in animals treated with ReGel
and ReGel/paclitaxel
The following results were obtained in the five animals
in which ReGel alone was applied to the graft on one side
and ReGel/paclitaxel was applied to the contralateral
graft. For the five grafts that received ReGel alone, four
grafts remained patent at eight weeks when the dogs were
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 1. Neointimal hyperplasia at the venous anastomosis of an untreated expanded polytetrafluoroethylene (ePTFE) graft explanted at eight weeks.
The section stained with hematoxylin and eosin shows that the hyperplastic tissue was comprised of nucleated cells in disarray (A). These cells
reacted strongly with anti-a actin, developed with a second antibody and alkaline phosphastase, appearing in brown color (B, 225× magnification).
In addition, there were abundant extracellular matrices that stained prominently with trichrome (blue color in C), van Gieson (violet color in D),
and alcian blue (periwinkle color in E).
sacrificed (Table 1). In the remaining dog (#4), the graft
that received ReGel alone was occluded at four weeks.
All five grafts that received ReGel/paclitaxel remained
patent at the time of sacrifice (8–9 weeks). It should be
emphasized, however, that graft patency, thrombosis, and
blood flow rate were not predetermined outcomes, since
the primary objective of this study was to specifically as-
sess neointimal hyperplasia by histology.
Plasma paclitaxel concentrations
The concentrations of paclitaxel from all peripheral
venous blood samples were below the detection limit of
the assay, which was 10 ng/mL.
Histology in animals treated with ReGel and ReGel
with paclitaxel
The animals that received bilateral graft placement
were sacrificed at 8 to 9 weeks. The histologic sections
were not available for proper grading of the arterial anas-
tomosis in one animal (#1). Bilateral grafts from the re-
maining four animals could be evaluated histologically,
and were included in the composite scoring described
below. The venous anastomosis of the graft treated with
ReGel alone from one animal (#4) was totally occluded
by thrombosis. Since the occlusion occurred early (at four
weeks) in this graft, sufficient time was not allowed for sig-
nificant neointimal hyperplasia to develop, making com-
parison between the two sides difficult. Therefore, that
animal was excluded from the data analysis of the venous
anastomoses. Bilateral venous grafts from the remaining
four animals were included in the composite scoring de-
scribed below. The histologic sections of the bilateral ar-
terial anastomoses of one animal (#4) are presented in
Figures 2A and B, while the sections of the bilateral ve-
nous anastomoses of another animal (#1) are presented
in Figures 3A and B.
The median hyperplasia score of the arterial anasto-
mosis in the grafts treated with ReGel alone was 2.65,
with an interquartile range of 1.33 to 3.78 (25th–75th
percentile), while the median score in the contralat-
eral grafts treated with ReGel/paclitaxel was 1.00,
with an interquartile range of 0.78 to 3.78 (N = 4
for each side; P = NS). The median hyperplasia
score of the venous anastomosis in the grafts treated
with ReGel alone was 1.35, with an interquartile
range from 0.90 to 2.20, while the median score in
the contralateral grafts treated with ReGel/paclitaxel
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Fig. 2. Arterial anastomosis of ePTFE grafts in animal #4 in response to ReGel alone or ReGel/paclitaxel (see Table 1). Two weeks after bilateral
arteriovenous graft placement between the femoral vessels, 2 mL of ReGel in liquid form were injected percutaneously to the perivascular area
around the anastomoses on one side, while 2 mL of ReGel in liquid form containing 0.26 mg of paclitaxel were injected to the anastomoses of the
contralateral graft. The animal was sacrificed at 8 weeks, and both grafts were retrieved. The sections were stained with hematoxylin and eosin.
Arterial anastomosis of graft that received ReGel alone (A). A nonocclusive thrombus can also be seen in the lumen. Arterial anastomosis of
contralateral graft that received ReGel with 0.26 mg of paclitaxel (B).
A B
Fig. 3. Venous anastomosis of ePTFE grafts in animal #1 in response to ReGel alone or ReGel/paclitaxel (see Table 1). Immediately after bilateral
arteriovenous graft placement between the femoral vessels, 2 mL of ReGel in gel form were applied directly to the perivascular area around
the anastomoses on one side, while 2 mL of ReGel in gel form containing 0.26 mg of paclitaxel were directly applied to the anastomoses of the
contralateral graft intraoperatively. The animal was sacrificed at 8 weeks, and both grafts were retrieved. The sections were stained with hematoxylin
and eosin. Venous anastomosis of graft that received ReGel alone (A). Venous anastomosis of contralateral graft that received ReGel with 0.26 mg
of paclitaxel (B).
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Fig. 4. Scores of neointimal hyperplasia at the arterial (red sym-
bols) and venous (blue symbols) anastomoses in response to treat-
ment using ReGel alone (labeled as control on the horizontal axis) or
ReGel/paclitaxel (labeled as paclitaxel on the horizontal axis). The de-
gree of neointimal hyperplasia at each available anastomosis was graded
by 5 independent blinded reviewers. The 5 scores were then averaged
and presented as a single composite value (either red or blue symbols
connected by broken lines) for each animal. For both arterial and ve-
nous anastomoses, the hexagons represent animal #1 (as described in
Table 1); squares represent animal #2; diamonds represent animal #3;
triangles represent animal #4; and circles represent animal #5. The his-
tology of the arterial anastomosis was unavailable for animal #1, and
that of the venous anastomosis was unavailable for animal #4. Overall,
ReGel/Paclitaxel decreased neointimal hyperplasia at both arterial and
venous anastomoses from a median score of 1.80 to 0.95 (black solid
line) (N = 8; P < 0.05).
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was 0.90, with an interquartile range of 0.58 to 1.13 (N =
4 for each side; P = NS). The median hyperplasia score of
both arterial and venous anastomoses in the grafts treated
with ReGel alone was 1.80, with an interquartile range of
0.90 to 3.05, while the median score in the contralateral
grafts treated with ReGel/paclitaxel was 0.95, with an in-
terquartile range of 0.70 to 1.50 (N = 8 for each side; P <
0.05 by Wilcoxon signed-rank test). A summary of the
scores is shown in Figure 4.
The hyperplasia score of the grafts treated with ReGel
alone or ReGel/paclitaxel in this group of experimen-
tal animals were also compared to the hyperplasia score
at the anastomoses in the animals in the pilot studies,
in which no ReGel was used. There were no statistical
differences (P > 0.05) in the scores at the arterial anasto-
moses, venous anastomoses, or arterial/venous combined
between the two groups.
DISCUSSION
We have established a dog model of arteriovenous
ePTFE grafts in order to examine strategies for the pre-
vention of neointimal hyperplasia. The histology in this
model resembles that observed in hyperplastic tissues
around PTFE grafts in human, as previously described by
other investigators [8, 9]. There were migration and pro-
liferation of vascular smooth muscle cells at the anasto-
moses and an abundance of extracellular matrix proteins
(Fig. 1). Because we have not extensively performed im-
munohistologic staining, such as those for some growth
factors and cell-specific proteins, the similarity of the
dog model with the human lesion cannot be definitively
ascertained. The ability to perform comprehensive im-
munohistology is partially limited by the availability of
species-specific antibodies for the dog. The rate of pro-
gression of the hyperplasia in the dog appears to be slower
than that reported in the porcine PTFE graft model, in
which only four weeks were necessary for aggressive le-
sions to develop [16]. While this slower and less extensive
development of hyperplasia may more closely resemble
the de novo lesions in human, this feature also represents
a disadvantage in employing the model for experimental
studies.
There have been very few controlled trials on strate-
gies to prevent the occlusion of synthetic hemodialysis
arteriovenous grafts. Sreedhara et al performed a ran-
domized, double-blind study, and found that the systemic
administration of dipyridamole was associated with a
lower rate of thrombosis compared to placebo [17]. The
sample size in that study was small. Further, stenosis as
a result of neointimal hyperplasia in the vascular access
was not specifically examined as an end point. Neither
were central vessels, such as the subclavian vein, exam-
ined for preexisting stenosis. A large multicenter trial is
currently being sponsored by the National Institute of
Diabetes and Digestive and Kidney Diseases to test the
efficacy of systemic administration of dipyridamole and
aspirin on the patency rate of PTFE grafts. The results of
that trial are not yet available.
A number of biological reagents have been found to
be effective in inhibiting neointimal hyperplasia in var-
ious animal models. Direct inhibition of cell growth by
disrupting mitosis of vascular smooth muscle cells can be
advantageous because the effect is independent of the
specific extracellular stimuli, such as specific growth fac-
tors, which may vary with the clinical circumstances. For
example, the growth factors produced following repeated
needle puncture of the graft may be different from those
produced as a result of mismatch in vessel size and com-
pliance.
Treatment using drugs, if successful, would be sim-
pler and more practical than most biological reagents.
A number of drugs have been shown to inhibit the
growth of vascular smooth muscle cells (e.g., heparin [18],
calcium channel blockers [19], angiotensin-converting
enzyme inhibitors [20], dipyridamole [21, 22], and pacli-
taxel [11, 12]). Attempts to reduce vascular stenosis in
various animal models by the systemic administration of
these agents have been largely unsuccessful. Of note is
that heparin is used almost universally for anticoagula-
tion during hemodialysis on a chronic basis, yet vascular
access stenosis occurs frequently in these patients. In con-
trast, the local administration of very high concentrations
of heparin reduced neointimal hyperplasia in PTFE grafts
of the inferior vena cava of rabbits [23]. Systemic admin-
istration of dipyridamole was found to be ineffective in
preventing the development of neointimal hyperplasia
following balloon injury of carotid arteries in the rat [24],
interposition PTFE grafts in the carotid artery of the goat
[25], and interposition venous grafts to the iliac artery
in the dog [26]. In contrast, continuous local delivery of
dipyridamole by infusing the drug into the adventitia for
more than two weeks was successful in partially inhibit-
ing intimal thickening after balloon injury in the carotid
artery of the rabbit [7]. These latter studies suggest that
the local perivascular delivery of antiproliferative agents
can be more effective than systemic administration. Lo-
cal drug delivery allows far higher local concentrations
of the drug with much lower likelihood of systemic side
effects. Because of the focal nature of most lesions in the
hemodialysis vascular access, the local delivery of phar-
macologic agents to mitigate the hyperplastic response of
smooth muscle cells appears ideal.
The challenge to localized drug delivery in this appli-
cation is to provide a clinically useful method that re-
tains the drug at the desired anatomic location without
its redistribution into the systemic circulation. Methods
based on drug-coated stents have been extensively stud-
ied in coronary arteries. For example, paclitaxel [15] or
sirolimus [27] incorporated into the drug-eluting stents
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have been reported to decrease the restenosis rate of
coronary arteries compared to conventional stents. The
scenario with hemodialysis grafts is different from that
with coronary stenosis, and percutaneous application of
drugs might be preferable for the following reasons.
Neointimal hyperplasia in the coronary artery is a sec-
ondary lesion resulting from the balloon angioplasty.
Placement of a drug-eluting stent to prevent the neointi-
mal hyperplasia at the time of angioplasty of the primary
atherosclerotic lesion is reasonable, and can be readily ac-
complished in many instances. In contrast, the neointimal
hyperplasia at the dialysis graft is often a primary lesion.
Angioplasty and stent placement are not necessary if the
hyperplasia can be prevented by other means. Applica-
tion of drugs to the luminal surface, such as that achieved
by drug-eluting stents, will invariably result in the entry
of a substantial amount of drug into the bloodstream. De-
tailed studies using labeled heparin have shown that the
drug is primarily delivered to regions where the stent has
direct contact with the tissue, while a significant portion of
the dose is in fact lost to the systemic circulation because
it resides in the arterial flow [28]. Developing a system
that can be applied perivascularly that would allow the
drug to preferentially diffuse into the vascular tissue and
the developing neointima within the graft would theo-
retically decrease that likelihood. The dialysis grafts are
superficial and are easily accessible via a percutaneous
needle. The drug depot can be readily replenished by in-
jecting ReGel percutaneously.
The present study suggests that the local delivery of pa-
clitaxel inhibits neointimal hyperplasia of arteriovenous
ePTFE grafts beyond any potential effect that might be
related to the presence of ReGel alone. The relative lack
of inhibitory effect of paclitaxel observed in some animals
might have been partly due to the mild degree of neointi-
mal hyperplasia on the control side (ReGel alone). In the
animals in which substantial hyperplasia was seen on the
control side (Fig. 4), the treatment with ReGel/paclitaxel
was associated with sizeable decreases in the hyperpla-
sia. Ideally, the experimental animal should include an
additional control that is composed of a graft in a third
limb that is not treated with either ReGel or paclitaxel.
There are at least two factors that prohibit this approach.
The first is a major one that relates to the ethics of animal
experimentation. The accepted ethics which are adopted
by most IACUC prohibit undue distress imposed on an
animal, such as the placement of three grafts instead of
two grafts. Placing grafts on three limbs prolongs the op-
eration, increases postoperative pain, and hinders the
movement of the animal. The second factor relates to
the inherent anatomic differences between the hind limbs
and the forelimbs of dogs, such that comparisons between
grafts placed in these two sites might be difficult.
The present data do not rule out the possibility that
ReGel actually enhances neointimal hyperplasia. Previ-
ous studies, however, have shown that ReGel did not
elicit any significant inflammatory response more than re-
sorbable sutures upon subcutaneous injection in rodents
[10]. The lack of inflammatory response in the perivascu-
lar tissues upon the injection of ReGel was also observed
in the present study. Further, there were no differences
between the hyperplasia score at the anastomoses in the
animals in the pilot studies and the corresponding val-
ues at the anastomoses that received ReGel alone in the
experimental animals. Although these were not paired
comparisons between two legs within the same animals,
the results nonetheless suggest that ReGel, per se, does
not enhance the development of hyperplasia. Perform-
ing an additional set of experiments in which the control
graft receives no treatment, and the contralateral graft
receives ReGel alone, would address this issue more di-
rectly. An intrinsic assumption for all experiments em-
ploying bilateral grafts is that both grafts would behave
and develop hyperplasia similarly, if they were not treated
with ReGel/paclitaxel or ReGel alone. It is, however,
reckoned that there are potential inherent differences in
anatomy and surgical techniques between the bilateral
grafts that might affect the development of neointimal
hyperplasia.
The usual dosages of paclitaxel employed in chemo-
therapy for malignant tumors are 135 or 175 mg/m2. The
peak plasma concentrations averaged 2.17 or 3.65 lg/mL
after intravenous infusion of these doses [29]. In con-
trast, the dosage employed in the present study was only
0.26 mg, which is approximately 1000-fold lower than the
clinical chemotherapy dose. The 0.26 mg was slowly re-
leased from the ReGel, presumably over several weeks.
Further, it was released locally to the interstitium around
the vascular access, instead of directly infused into the
blood stream. It is, therefore, not surprising that the sys-
temic plasma level of paclitaxel was below the detection
limit of the assay (10 ng/mL). With these low plasma
concentrations, systemic side effects are expected to be
absent.
It should also be emphasized that the primary purpose
of this study was to test the feasibility of local drug deliv-
ery to inhibit neointimal hyperplasia at the anastomosis
of arteriovenous ePTFE grafts. It was not designed to
prevent or examine thrombosis, blood flow rates through
the graft, or occlusion. The most successful strategy for
prolonging hemodialysis graft patency could be the pre-
vention of neointimal hyperplasia by the local delivery of
an antiproliferative agent in conjunction with antiplatelet
agents administered locally or orally, and improved
design of the geometry and compliance of the grafts.
CONCLUSION
The approach described in this report is not lim-
ited to antiproliferative agents, but is applicable to any
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drug with toxicities that limit its systemic administration.
Additional work will be necessary to test this hypothe-
sis, and to establish the optimal types, dosages, and ad-
ministration schedules for these drugs. In the absence of
stenosis, thrombosis and subsequent occlusion should be
markedly decreased and grafts would evolve into a good
option for permanent hemodialysis vascular access.
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